#Singapore #Cancer Immunotherapy #ACM Biolabs #ACM-CpG

ACM Biolabs Reports Positive Early Findings in Cancer Treatment

ACM Biolabs, a clinical-stage biotechnology firm specializing in advanced nanoparticle-based immunotherapies, has recently announced some promising early results from its ongoing Phase 1 study of ACM-CpG. This innovative treatment involves a TLR9 agonist, designed using the company's proprietary polymersome platform, and it is being evaluated through a strategic partnership with the National Cancer Centre Singapore (NCCS).

The Phase 1 study (NCT06587295) focuses on patients suffering from advanced solid tumors. Early clinical data appears to affirm preclinical findings suggesting that ACM-CpG's nanoparticle formulation fundamentally alters the mechanism of action of CpG. It enables myeloid modulation via extensive TLR9 engagement in “cold” tumors, which typically do not respond well to existing immunotherapies.

Participants in the study are being monitored to evaluate the safety, tolerability, and pharmacodynamic effects of ACM-CpG. Initial findings are notably encouraging. Patients treated intramuscularly with ACM-CpG—administered weekly or biweekly at a low dosage of 0.25 mg—have shown significant systemic immune activation, as evidenced by various immuno-biomarker data. Furthermore, the treatment has displayed an excellent safety profile, with no dose-limiting toxicities reported to date.

Dr. Madhavan Nallani, CEO of ACM Biolabs, explained that while TLR9 has long been recognized as a validated immunological target, its potential has been limited by delivery and safety challenges. He stated, “Our nanoparticle-based intramuscular administration facilitates robust systemic immune activation while maintaining a superb safety profile. This opens up not just the possibility for combination therapies but also for targeted monotherapy options in patient groups with few treatment alternatives.”

ACM Biolabs also envisions that this platform could eventually support additional routes of administration, allowing for tailored treatment strategies across a range of tumor scenarios and addressing significant unmet medical needs.

Dr. Amit Jain, a Senior Consultant at NCCS and head of the Medical Oncology Department, expressed his excitement about the findings, stating, “The safety profile and distinct pharmacodynamic activity we have observed so far are very encouraging, with two of the three patients treated at the 0.25 mg dosage managing to control their disease for eight months on monotherapy alone. We look forward to exploring ways to optimize delivery and maximize therapeutic potential for patients with advanced cancer.”

The study is partially funded by Singapore’s Industry Alignment Fund – Pre-Positioning (IAF-PP), which promotes strategic collaborations between industry and research institutes. ACM-CpG is currently being studied in patients with advanced cancers, including head and neck, lung, bladder, and renal cancer, revealing its multifaceted potential in oncology.

ACM Biolabs is headquartered in Singapore and has offices in Basel, Switzerland, and Sydney, Australia. The company specializes in developing targeted vaccines and immunotherapies through its proprietary polymer-lipid hybrid nanoparticle platform. Its pipeline includes candidates in oncology, infectious diseases, and inflammation, with a strong emphasis on precise immunomodulation and next-generation drug delivery.

For updates and more information on ACM Biolabs and their innovative research, interested parties can follow their developments and subscribe to their communications.